- Trial phase
- Approved (US approval recorded 2020-03-25); no active Phase 2/3 industry-sponsored trials for ozanimod/Zeposia in SecBot
- Time to market
- Already on the market, approved (US FDA approval recorded 2020-03-25 in SecBot's local catalyst data); commercialized by Bristol Myers Squibb.
- Why 3/10
- Zeposia is already approved and marketed, and no Zeposia-specific PDUFA, pivotal readout, or label-expansion catalyst appears in local FDA/event data for the next ~12 months, so there is no dated binary to trade, and at BMY scale this one product is a small part of a huge portfolio.
There is no near-term Zeposia-specific event to trade, the drug's binary (approval) already passed in 2020, and BMY's scheduled FDA catalysts in local data are other assets (iberdomide PDUFA 2026-08-17; Reblozyl PDUFA 2027-03-11; mezigdomide PDUFA 2027-05-13). Watch BMY's quarterly filings (10-Q/8-K) for the Zeposia sales line if you want to track this product specifically; the stock is more likely to move on BMY's portfolio-wide results and those other catalysts than on Zeposia alone.
Price Chart
Executive Summary
Zeposia (generic name ozanimod) is an oral, marketed Bristol Myers Squibb drug, SecBot's local FDA-catalyst records log a Zeposia FDA-approval event dated 2020-03-25 with a positive 1-day (+6.11%) and 5-day (+10.46%) stock reaction around it, and the drug is listed among BMY's products in the company's Q2 2026 earnings 8-K analysis. BMY trades near $65.31 (2026-07-31 close), with analyst consensus "hold", a mean price target of $64.91, and short interest of ~44.9M shares (~2.2% of estimated shares outstanding) at the 2026-07-15 settlement. Net read: a real but modest commercial asset inside a mega-cap, with no near-term binary of its own, hence neutral.
How It Works
Zeposia (ozanimod) is an oral drug from the class of sphingosine 1-phosphate (S1P) receptor modulators, it keeps certain immune cells from escaping lymph nodes, reducing the inflammatory immune traffic that drives autoimmune disease.
Trial Status
SecBot's local FDA-catalyst log shows a Zeposia FDA-approval event dated 2020-03-25 (BMY stock +6.11% over 1 day and +10.46% over 5 days around it in the local outcomes record). No Zeposia-specific regulatory filings, label-expansion submissions, or scheduled trial readouts appear in local FDA catalyst/event data for the trailing year or the next 12 months. Zeposia is named among BMY's marketed products in the company's Q2 2026 earnings 8-K filing analysis.
The Two-Sided Case
Upcoming Catalysts
- None specific to Zeposia in local data for the next ~12 months.
- BMY-level dated catalysts from local FDA data: iberdomide PDUFA 2026-08-17 (relapsed/refractory multiple myeloma); Reblozyl PDUFA 2027-03-11 (myelofibrosis-associated anemia); mezigdomide PDUFA 2027-05-13 (RRMM).
- BMY quarterly results (next 10-Q/8-K), watch the Zeposia revenue line.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report